For adults living with persistent, difficult-to-treat pain, IV ketamine may be considered in selected cases—particularly when neuropathic pain or complex regional pain syndrome remains disruptive despite conventional treatment. At Ketamine Wellness Florida, care begins with an individualized physician evaluation and realistic discussion of the evidence.
Chronic pain can affect far more than the location that hurts. Persistent pain may disrupt sleep, mobility, concentration, employment, exercise, relationships, emotional health and overall quality of life.
Treatment depends heavily on the cause and type of pain. A comprehensive plan may involve medications, physical therapy, interventional procedures, rehabilitation, behavioral approaches, treatment of an underlying disease, or combinations of these strategies.
For some people, however, clinically significant pain continues despite reasonable treatment efforts. Ketamine has attracted interest in this setting because it affects glutamatergic signaling and NMDA receptors, mechanisms involved in pain processing, central sensitization and neural signaling.
The important question is not simply whether ketamine can reduce pain. It is whether the patient's specific pain condition, medical history, prior treatments and goals make IV ketamine a reasonable option to consider.
Neuropathic pain develops from disease or injury affecting the somatosensory nervous system. Ketamine has been evaluated in randomized trials and systematic reviews for several neuropathic pain populations. Some analyses report reductions in pain, while also emphasizing substantial differences among study protocols and generally limited certainty regarding long-term benefit.
CRPS is one of the chronic pain conditions most frequently discussed in the IV ketamine literature. Randomized trials and systematic reviews have reported pain reduction in some patients, although response varies and improvement in pain does not necessarily mean equivalent improvement in physical function.
Meta-analytic evidence has found short-term analgesic benefit following IV ketamine in certain refractory chronic pain populations. The duration of benefit varies considerably among patients and studies.
Researchers have investigated ketamine partly because NMDA receptor activity can participate in central sensitization, wind-up and amplification of persistent pain signaling.
Studies differ in diagnosis, dose, infusion length, outcome measures and follow-up. A positive study in one pain syndrome should not automatically be generalized to every chronic pain condition.
Responsible treatment begins with a clear understanding of what the research can support and what cannot be predicted in advance.
Neuropathic pain, inflammatory pain, musculoskeletal pain, nociplastic pain and CRPS are not interchangeable diagnoses. Determining the likely pain mechanism is an important part of deciding whether ketamine deserves consideration.
Some clinical studies report meaningful reductions in pain following ketamine treatment. Others show smaller or inconsistent effects. No clinician can reliably guarantee in advance how much benefit an individual patient will experience.
Even when ketamine produces a clinically meaningful response, improvement may diminish over time. Follow-up should examine both symptom relief and whether treatment meaningfully improves daily function.
Physical therapy, movement, sleep optimization, psychological support, medication management, procedures and treatment of underlying disease may remain important even when ketamine is included in the care plan.
Cardiovascular health, blood pressure, liver history, psychiatric history, medications, substance use, pregnancy and other clinical factors can alter the risk-benefit analysis.
Chronic pain involves complex interactions among peripheral nerves, the spinal cord, the brain, inflammation, learning, stress and multiple neurotransmitter systems.
Ketamine is a noncompetitive antagonist of the NMDA receptor, a glutamate receptor involved in neural signaling and pain processing. This pharmacology is one reason ketamine has been studied in difficult-to-treat pain states.
In some chronic pain conditions, the nervous system can become increasingly responsive to sensory input. Researchers describe processes such as central sensitization and wind-up, in which pain signaling becomes amplified or persists beyond the original tissue injury.
Burning pain, electrical or shooting sensations, allodynia and hyperalgesia can occur when the nervous system itself is injured or dysfunctional. Because glutamate and NMDA signaling participate in these pathways, ketamine has been investigated as a potential analgesic strategy.
Persistent pain can involve biological, neurological, psychological and social factors simultaneously. Modifying one receptor system cannot be assumed to address every contributor to chronic pain or restore function by itself.
Candidacy is determined medically. Having chronic pain alone does not automatically make someone an appropriate candidate for IV ketamine.
The location, mechanism, diagnosis, duration and clinical features of persistent pain should be understood as clearly as possible before discussing treatment.
Medication trials, physical therapy, injections, procedures, surgery, rehabilitation and other previous interventions help establish what has already been attempted and with what result.
Cardiovascular status, blood pressure, liver function, neurological history, pregnancy and other medical considerations can influence treatment safety.
Opioids, sedatives, stimulants, psychiatric medications, anticoagulants, supplements and other drugs should be reviewed as part of individualized treatment planning.
Pain scores matter, but so do sleep, movement, work, independence, exercise tolerance and other functional outcomes that affect daily life.
Treatment planning should identify what would constitute meaningful improvement rather than assuming complete or permanent elimination of chronic pain.
A structured process helps determine whether IV ketamine is medically appropriate and whether continued treatment makes sense based on tolerability, pain response and function.
Speak with our team about your chronic pain diagnosis, symptoms, previous treatments, medications and what you hope to improve.
A physician reviews relevant medical history, pain history, medication use, potential contraindications and treatment goals.
If appropriate, ketamine is administered intravenously in a controlled clinical environment with physiologic monitoring and medical oversight.
Pain, function, side effects and treatment goals are reassessed. Continued treatment should depend on the patient's individual clinical response.
Persistent pain is rarely explained by one receptor, one medication or one treatment modality. Long-term function may depend on treating an underlying condition while also addressing movement, sleep, strength, nervous-system sensitivity, psychological stress and medication burden.
When ketamine is appropriate, it can be considered as one component of a broader treatment strategy rather than a replacement for comprehensive pain care.
Dr. Jarrod Wilson is a South Florida physician specializing in anesthesiology. He attended medical school at the University of Miami and completed anesthesiology residency training at Mount Sinai Medical Center of Miami Beach.
Ketamine has a long history in anesthesiology and pain medicine. Dr. Wilson's anesthesiology background includes experience with intravenous medications, patient monitoring, physiology and medication safety.
Ketamine can temporarily alter blood pressure, heart rate, perception, coordination and level of awareness. Appropriate patient selection, individualized dosing and clinical monitoring are therefore important parts of treatment.
Ketamine Wellness Florida provides physician-guided IV ketamine care in Fort Lauderdale within The Remedy Health & Wellness. We serve adults from Fort Lauderdale, Broward County and surrounding South Florida communities who are exploring additional options for persistent and difficult-to-treat pain.
If you are researching ketamine for chronic pain, neuropathic pain, nerve pain, CRPS or refractory pain , the first step is a clinical conversation. We can review the evidence, discuss safety and limitations, and determine whether a physician evaluation is appropriate.
Clinical evidence for ketamine in chronic pain differs by diagnosis and remains an evolving area of pain medicine. These publications provide context for the educational information on this page.
These answers are educational and cannot determine whether IV ketamine is appropriate for an individual patient.
Speak with the Ketamine Wellness Florida care team in Fort Lauderdale to discuss your pain history, previous treatments and questions about physician-guided IV ketamine therapy.
For adults living with persistent, difficult-to-treat pain, IV ketamine may be considered in selected cases—particularly when neuropathic pain or complex regional pain syndrome remains disruptive despite conventional treatment. At Ketamine Wellness Florida, care begins with an individualized physician evaluation and realistic discussion of the evidence.
Chronic pain can affect far more than the location that hurts. Persistent pain may disrupt sleep, mobility, concentration, employment, exercise, relationships, emotional health and overall quality of life.
Treatment depends heavily on the cause and type of pain. A comprehensive plan may involve medications, physical therapy, interventional procedures, rehabilitation, behavioral approaches, treatment of an underlying disease, or combinations of these strategies.
For some people, however, clinically significant pain continues despite reasonable treatment efforts. Ketamine has attracted interest in this setting because it affects glutamatergic signaling and NMDA receptors, mechanisms involved in pain processing, central sensitization and neural signaling.
The important question is not simply whether ketamine can reduce pain. It is whether the patient's specific pain condition, medical history, prior treatments and goals make IV ketamine a reasonable option to consider.
Chronic pain is not one disease. Evidence varies considerably by diagnosis, dose, infusion duration, treatment schedule and study design.
Neuropathic pain develops from disease or injury affecting the somatosensory nervous system. Ketamine has been evaluated in randomized trials and systematic reviews for several neuropathic pain populations. Some analyses report reductions in pain, while also emphasizing substantial differences among study protocols and generally limited certainty regarding long-term benefit.
CRPS is one of the chronic pain conditions most frequently discussed in the IV ketamine literature. Randomized trials and systematic reviews have reported pain reduction in some patients, although response varies and improvement in pain does not necessarily mean equivalent improvement in physical function.
Meta-analytic evidence has found short-term analgesic benefit following IV ketamine in certain refractory chronic pain populations. The duration of benefit varies considerably among patients and studies.
Researchers have investigated ketamine partly because NMDA receptor activity can participate in central sensitization, wind-up and amplification of persistent pain signaling.
Studies differ in diagnosis, dose, infusion length, outcome measures and follow-up. A positive study in one pain syndrome should not automatically be generalized to every chronic pain condition.
Responsible treatment begins with a clear understanding of what the research can support and what cannot be predicted in advance.
Neuropathic pain, inflammatory pain, musculoskeletal pain, nociplastic pain and CRPS are not interchangeable diagnoses. Determining the likely pain mechanism is an important part of deciding whether ketamine deserves consideration.
Some clinical studies report meaningful reductions in pain following ketamine treatment. Others show smaller or inconsistent effects. No clinician can reliably guarantee in advance how much benefit an individual patient will experience.
Even when ketamine produces a clinically meaningful response, improvement may diminish over time. Follow-up should examine both symptom relief and whether treatment meaningfully improves daily function.
Physical therapy, movement, sleep optimization, psychological support, medication management, procedures and treatment of underlying disease may remain important even when ketamine is included in the care plan.
Cardiovascular health, blood pressure, liver history, psychiatric history, medications, substance use, pregnancy and other clinical factors can alter the risk-benefit analysis.
Chronic pain involves complex interactions among peripheral nerves, the spinal cord, the brain, inflammation, learning, stress and multiple neurotransmitter systems.
Ketamine is a noncompetitive antagonist of the NMDA receptor, a glutamate receptor involved in neural signaling and pain processing. This pharmacology is one reason ketamine has been studied in difficult-to-treat pain states.
In some chronic pain conditions, the nervous system can become increasingly responsive to sensory input. Researchers describe processes such as central sensitization and wind-up, in which pain signaling becomes amplified or persists beyond the original tissue injury.
Burning pain, electrical or shooting sensations, allodynia and hyperalgesia can occur when the nervous system itself is injured or dysfunctional. Because glutamate and NMDA signaling participate in these pathways, ketamine has been investigated as a potential analgesic strategy.
Persistent pain can involve biological, neurological, psychological and social factors simultaneously. Modifying one receptor system cannot be assumed to address every contributor to chronic pain or restore function by itself.
Candidacy is determined medically. Having chronic pain alone does not automatically make someone an appropriate candidate for IV ketamine.
The location, mechanism, diagnosis, duration and clinical features of persistent pain should be understood as clearly as possible before discussing treatment.
Medication trials, physical therapy, injections, procedures, surgery, rehabilitation and other previous interventions help establish what has already been attempted and with what result.
Cardiovascular status, blood pressure, liver function, neurological history, pregnancy and other medical considerations can influence treatment safety.
Opioids, sedatives, stimulants, psychiatric medications, anticoagulants, supplements and other drugs should be reviewed as part of individualized treatment planning.
Pain scores matter, but so do sleep, movement, work, independence, exercise tolerance and other functional outcomes that affect daily life.
Treatment planning should identify what would constitute meaningful improvement rather than assuming complete or permanent elimination of chronic pain.
A structured process helps determine whether IV ketamine is medically appropriate and whether continued treatment makes sense based on tolerability, pain response and function.
Speak with our team about your chronic pain diagnosis, symptoms, previous treatments, medications and what you hope to improve.
A physician reviews relevant medical history, pain history, medication use, potential contraindications and treatment goals.
If appropriate, ketamine is administered intravenously in a controlled clinical environment with physiologic monitoring and medical oversight.
Pain, function, side effects and treatment goals are reassessed. Continued treatment should depend on the patient's individual clinical response.
Persistent pain is rarely explained by one receptor, one medication or one treatment modality. Long-term function may depend on treating an underlying condition while also addressing movement, sleep, strength, nervous-system sensitivity, psychological stress and medication burden.
When ketamine is appropriate, it can be considered as one component of a broader treatment strategy rather than a replacement for comprehensive pain care.
Dr. Jarrod Wilson is a South Florida physician specializing in anesthesiology. He attended medical school at the University of Miami and completed anesthesiology residency training at Mount Sinai Medical Center of Miami Beach.
Ketamine has a long history in anesthesiology and pain medicine. Dr. Wilson's anesthesiology background includes experience with intravenous medications, patient monitoring, physiology and medication safety.
Ketamine can temporarily alter blood pressure, heart rate, perception, coordination and level of awareness. Appropriate patient selection, individualized dosing and clinical monitoring are therefore important parts of treatment.
Ketamine Wellness Florida provides physician-guided IV ketamine care in Fort Lauderdale within The Remedy Health & Wellness. We serve adults from Fort Lauderdale, Broward County and surrounding South Florida communities who are exploring additional options for persistent and difficult-to-treat pain.
If you are researching ketamine for chronic pain, neuropathic pain, nerve pain, CRPS or refractory pain , the first step is a clinical conversation. We can review the evidence, discuss safety and limitations, and determine whether a physician evaluation is appropriate.
Clinical evidence for ketamine in chronic pain differs by diagnosis and remains an evolving area of pain medicine. These publications provide context for the educational information on this page.
These answers are educational and cannot determine whether IV ketamine is appropriate for an individual patient.
Speak with the Ketamine Wellness Florida care team in Fort Lauderdale to discuss your pain history, previous treatments and questions about physician-guided IV ketamine therapy.